Release Date: November 20, 2017
Expiration Date: November 30, 2019 (subject to change)
- CE for this activity will not be available after this date.
Reference Number: 17022536
Approximately 2% to 3% of the US population (an estimated 7.5 million Americans) has psoriasis. Plaque psoriasis, which affects about 80% to 90% of individuals with psoriasis, is often disfiguring and painful. Psoriatic arthritis (PsA) occurs in approximately 30% of patients with psoriasis and can be associated with additional problems and comorbidities. Despite the availability of effective treatment options, many patients with psoriasis and PsA are not receiving optimal treatment needed to clear their symptoms and improve quality of life. This program will examine the pathogenesis of psoriasis and PsA, evidence-based guidelines for diagnosis and treatment, and the expanding therapeutic options available for each condition.
This is a recorded version of live presentations offered through the AANP Continuing Education Series. If you received credit for this activity by attending a live session, you may not receive duplicate credit for the same content in a different format.
CE Credit Instructions
- Read this activity description, including objectives and disclosures.
- Complete the educational content completely:
- Video Presentations: Watch all video presentations completely.
- Review all additional materials provided (handouts, posttest reviews, all other downloadable resources).
- After completing all content, go to Steps to Receive Credit to complete the posttest and evaluation to receive full AANP CE/Rx credit. If other types of credit are offered, these options will be available after completing the activity evaluation.
Upon completion of this activity, the participant should be able to:
- Summarize the epidemiology and pathophysiology of psoriasis and PsA.
- Describe the diagnosis, disease classification, and assessment associated with psoriasis and PsA.
- Incorporate patient preferences and shared decision making into tailored treatment plans for patients with psoriasis and PsA.
- Evaluate the efficacy and safety of recently available therapies for the management of psoriasis and PsA.
Margaret Bobonich, DNP, FNP-C, DCNP, FAANP
This activity was planned in accordance with AANP Accreditation Standards and Policies. It was developed by the American Association of Nurse Practitioners in cooperation with MCM Education, Newtown, PA. This program is supported by educational funding provided by Novartis Pharmaceuticals and Amgen.
Dr. Bobonich discloses that she has served on the Speakers Bureau and as a consultant for Eli Lilly and Company.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
For questions about this online CE activity, or more information concerning the AANP CE Center, contact the AANP CE Center Manager at CECenter@aanp.org.